The latest price target for Kura Oncology (NASDAQ:KURA) was reported by HC Wainwright & Co. on February 27, 2025. The analyst firm set a price target for $40.00 expecting KURA to rise to within 12 months (a possible 418.81% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Kura Oncology (NASDAQ:KURA) was provided by HC Wainwright & Co., and Kura Oncology reiterated their buy rating.

There is no last upgrade for Kura Oncology

The last downgrade for Kura Oncology Inc happened on October 14, 2024 when Stifel changed their price target from $26 to $19 for Kura Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on February 27, 2025 so you should expect the next rating to be made available sometime around February 27, 2026.

While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a reiterated with a price target of $40.00 to $40.00. The current price Kura Oncology (KURA) is trading at is $7.71, which is out of the analyst’s predicted range.